<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

New Ex Vivo PDX Compound Screening Platform

Patient-derived xenograft (PDX) models are in high demand in preclinical drug development due to their advantages over conventional 2D culture systems. These include a close molecular, histopathological, and heterogeneic reflection of the original tumor (more highly conserved than cell lines/GEMM) and the correlation between PDX and clinical drug response profiles.